To include your compound in the COVID-19 Resource Center, submit it here.

NICE backs Soliris without lifting veil

The U.K.'s NICE issued a final evaluation determination recommending Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to treat atypical hemolytic uremic syndrome (aHUS) without receiving the specific answers it sought

Read the full 309 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE